CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

Bold Therapeutics Reaches Enrollment Midpoint in Randomized Phase 2 Trial of BOLD-100 in Second-Line Metastatic Colorectal Cancer

Phase 2BOLD-100

Read the original article

Published by PR Newswire Biotech on October 15, 2026 12:49 PM

Read Original